11 news items
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
TAK
16 May 24
people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us
yktoan2rctyq06iv2bxgrenzvlodlxl5qhcuqgj8ujpmba 88a
TAK
22 Apr 24
to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded
ioa8vfucl hk1o5595hhwnz0yh110jl0yndv3p39bv8fqgwuyqwpl
TAK
18 Apr 24
headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries
g3pefoc
TAK
26 Mar 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet
t242hetbr4mmhxopyvyv2 d1
TAK
13 Mar 24
-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees
jdr959ng32jb47kvu3r42rb1c
TAK
26 Feb 24
and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us
b2b84q7ytdcq1cbs23jbflj1v46mjs7xpk u9ximvgynf0zwy
TAK
26 Feb 24
-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology
- Prev
- 1
- Next